Spinoff talk has surrounded Pfizer (PFE) for some time now following a business unit review a couple of years ago. That ultimately led to the sale of its nutritional unit and the successful IPO of ~20% of its animal health business, Zoetis (ZTS) earlier this year. Investors have been hoping for something bigger though,...
Read More »
Pfizer (PFE) generated a lot of buzz last year when it announced it was considering strategic options for several of its units. Its nutrition business has since been sold to Nestle for over $11b in cash and this week will bring about the IPO carve out of its animal health division, now known as...
Read More »
Whenever a corporate executive has to publicly state that they will not be spinning something off, it’s generally only a matter of time. This is likely the case with GlaxoSmithKline(GSK) and its majority-owned Viiv Healthcare unit. Viiv, of which Glaxo owns 76.5%, recently filed for approval for its anti-HIV drug, dolutegravir. If the drug...
Read More »
There are many hundreds of thousands of words in the English language, and zoetic is not one of the more common. The word, meaning “of or relating to life”, is the inspiration for Zoetis, the new name for Pfizer’s (PFE) soon to be independent Animal Health business. After over a year of speculation as...
Read More »
